Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Please scroll or swipe to the right to view the full content.
Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xeljanz tofacitinib Cancelled
Beleodaq Belinostat Withdrawn
Blincyto Blinatumomab Withdrawn
Admelog Insulin lispro Cancelled
TBD Cabozantinib Withdrawn
TBD Rituximab Cancelled
Translarna ataluren Cancelled
Tecentriq Atezolizumab Withdrawn
Xospata Gilteritinib Reimburse with clinical criteria and/or conditions Complete
TBD Entrectinib Withdrawn
Atriance Nelarabine Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
Ogivri Trastuzumab Withdrawn
Zytiga Abiraterone Withdrawn
TBC filgrastim Cancelled
Erbitux Cetuximab Cancelled
TBD Bevacizumab Cancelled
Ibrance Palbociclib Withdrawn
Adcetris Brentuximab vedotin Withdrawn
Venclexta Venetoclax Withdrawn
Cyramza Ramucirumab Cancelled
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Onivyde Nanoliposomal Irinotecan Cancelled
Avastin Bevacizumab Withdrawn